Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 11, 2011, Pages 1517-1523

  Reeves, Emer P ^a   Williamson, Michael ^a,b   O'Neill, Shane J ^a   Greally, Peter ^b   McElvaney, Noel G ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Cystic fibrosis; Glycosaminoglycans; IL 8; Nebulized hypertonic saline; Proteases

Indexed keywords

GLYCOSAMINOGLYCAN; INTERLEUKIN 8; SODIUM CHLORIDE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFECT; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE ACTIVATION; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ADMINISTRATION, INHALATION; ADULT; BLOTTING, WESTERN; BRONCHOALVEOLAR LAVAGE FLUID; CYSTIC FIBROSIS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSAMINOGLYCANS; HUMANS; INFLAMMATION; INTERLEUKIN-8; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; SALINE SOLUTION, HYPERTONIC; SPUTUM; YOUNG ADULT;

EID: 79957957677     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201101-0072OC     Document Type: Article

References (60)

1. Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 2007;13:231-240. (Pubitemid 46836874)
2. App EM, Baran D, Dab I, Malfroot A, Coffiner M, Vanderbist F, King M. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized nacystelyn in cystic fibrosis. Eur Respir J 2002;19:294-302. (Pubitemid 34162831)
3. Vasconcellos CA, Allen PG, Wohl ME, Drazen JM, Janmey PA, Stossel TP. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994;263:969-971. (Pubitemid 24094561)
4. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT. National Hypertonic Saline in Cystic Fibrosis (NHSCF) study group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240. (Pubitemid 43113028)
5. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-250. (Pubitemid 43113029)
6. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, Thompson S, Bush A, Wallis C. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358:1316-1321. (Pubitemid 33016495)
7. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-642. (Pubitemid 24276863)
8. King M, Dasgupta B, Tomkiewicz RP, Brown NE. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 1997;156:173-177. (Pubitemid 27293184)
9. Riedler J, Reade T, Button B, Robertson CF. Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. J Paediatr Child Health 1996;32:48-50. (Pubitemid 26141551)
10. Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bautovich GJ, King M, Bye PT. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997;52:900-903. (Pubitemid 27473934)
11. Robinson M, Regnis JA, Bailey DL, King M, Bautovich GJ, Bye PT. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996;153:1503-1509. (Pubitemid 26141332)
12. Wark PA, McDonald V, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2005;CD001506.
13. Wills PJ, Hall RL, Chan W, Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest 1997;99:9-13. (Pubitemid 27058287)
14. Gould NS, Gauthier S, Kariya CT, Min E, Huang J, Brian DJ. Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury. Respir Res 2010;11:119.
15. Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med 2006;12:445-452. (Pubitemid 44624606)
16. Badurdeen S, Ross-Russell R. Question 2: should hypertonic saline be used in patients with cystic fibrosis who respond unsatisfactorily to recombinant deoxyribonuclease? Arch Dis Child 2010;95:562-564.
17. Richman-Eisenstat JB, Jorens PG, Hebert CA, Ueki I, Nadel JA. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol 1993;264:L413-L418. (Pubitemid 23125320)
18. Tabary O, Zahm JM, Hinnrasky J, Couetil JP, Cornillet P, Guenounou M, Gaillard D, Puchelle E, Jacquot J. Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro. Am J Pathol 1998;153:921-930. (Pubitemid 28419044)
19. Muhlebach MS, Noah TL. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am J Respir Crit Care Med 2002;165:911-915. (Pubitemid 34774656)
20. Kelly E, Greene CM, McElvaney NG. Targeting neutrophil elastase in cystic fibrosis. Expert Opin Ther Targets 2008;12:145-157. (Pubitemid 351284958)
21. Kettle AJ, Chan T, Osberg I, Senthilmohan R, Chapman AL, Mocatta TJ, Wagener JS. Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis. Am J Respir Crit Care Med 2004;170:1317-1323. (Pubitemid 39657196)
22. Goger B, Halden Y, Rek A, Mosl R, Pye D, Gallagher J, Kungl AJ. Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites. Biochemistry 2002;41:1640-1646. (Pubitemid 34112754)
23. Marshall LJ, Ramdin LS, Brooks T, DPhil PC, Shute JK. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 2003;171:2057-2065. (Pubitemid 36966489)
24. Bhaskar KR, Turner BS, Grubman SA, Jefferson DM, LaMont JT. Dysregulation of proteoglycan production by intrahepatic biliary epithelial cells bearing defective (delta-f508) cystic fibrosis transmembrane conductance regulator. Hepatology 1998;27:7-14. (Pubitemid 28041527)
25. Hilliard TN, Regamey N, Shute JK, Nicholson AG, Alton EW, Bush A, Davies JC. Airway remodelling in children with cystic fibrosis. Thorax 2007;62:1074-1080. (Pubitemid 350206200)
26. Solic N, Wilson J, Wilson SJ, Shute JK. Endothelial activation and increased heparan sulfate expression in cystic fibrosis. Am J Respir Crit Care Med 2005;172:892-898. (Pubitemid 41369074)
27. Khatri IA, Bhaskar KR, Lamont JT, Sajjan SU, Ho CK, Forstner J. Effect of chondroitinase abc on purulent sputum from cystic fibrosis and other patients. Pediatr Res 2003;53:619-627. (Pubitemid 36406732)
28. Rahmoune H, Lamblin G, Lafitte JJ, Galabert C, Filliat M, Roussel P. Chondroitin sulfate in sputum from patients with cystic fibrosis and chronic bronchitis. Am J Respir Cell Mol Biol 1991;5:315-320.
29. Sahu SC. Hyaluronic acid. An indicator of pathological conditions of human lungs? Inflammation 1980;4:107-112.
30. Wyatt HA, Dhawan A, Cheeseman P, Mieli-Vergani G, Price JF. Serum hyaluronic acid concentrations are increased in cystic fibrosis patients with liver disease. Arch Dis Child 2002;86:190-193. (Pubitemid 34250864)
31. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ, Wells TN. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999;38:12959-12968.
32. Krieger E, Geretti E, Brandner B, Goger B, Wells TN, Kungl AJ. A structural and dynamic model for the interaction of interleukin-8 and glycosaminoglycans: Support from isothermal fluorescence titrations. Proteins 2004;54:768-775. (Pubitemid 38298795)
33. Williamson MR, Reeves EP, O'Neill SJ, Greally P, McElvaney NG. Glycosamoinoglycans regulate cytokine profiles in the lungs of patients with cystic fibrosis. Am J Respir Crit Care Med 2009;179:A1200.
34. Bergsson G, Reeves EP, McNally P, Chotirmall SH, Greene CM, Greally P, Murphy P, O'Neill SJ, McElvaney NG. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol 2009;183:543-551.
35. Reeves EP, Lu H, Jacobs HL, Messina CG, Bolsover S, Gabella G, Potma EO, Warley A, Roes J, Segal AW. Killing activity of neutrophils is mediated through activation of proteases by K1 flux. Nature 2002;416:291-297. (Pubitemid 34260237)
36. Weathington NM, van Houwelingen AH, Noerager BD, Jackson PL, Kraneveld AD, Galin FS, Folkerts G, Nijkamp FP, Blalock JE. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 2006;12:317-323. (Pubitemid 43355080)
37. Frevert CW, Kinsella MG, Vathanaprida C, Goodman RB, Baskin DG, Proudfoot A, Wells TN, Wight TN, Martin TR. Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. Am J Respir Cell Mol Biol 2003;28:464-472. (Pubitemid 36399368)
38. Marquezini MV, Strunz CM, Dallan LA, Toledo OM. Glycosaminoglycan distribution in atherosclerotic saphenous vein grafts. Cardiology 1995;86:143-146.
39. Negrine DPA, De Luca G, Miserocchi G. Proteoglycans in lung disease. New York: Marcel Dekker; 2000.
40. Suki B, Ito S, Stamenovic D, Lutchen KR, Ingenito EP. Biomechanics of the lung parenchyma: critical roles of collagen and mechanical forces. J Appl Physiol 2005;98:1892-1899. (Pubitemid 40570805)
41. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TN, Kosco-Vilbois MH. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003;100:1885-1890. (Pubitemid 36254543)
42. Hoogewerf AJ, Kuschert GS, Proudfoot AE, Borlat F, Clark-Lewis I, Power CA, Wells TN. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 1997;36:13570-13578. (Pubitemid 27481603)
43. Lortat-Jacob H, Grosdidier A, Imberty A. Structural diversity of heparan sulfate binding domains in chemokines. Proc Natl Acad Sci USA 2002;99:1229-1234. (Pubitemid 34136475)
44. Reeves EP, Williamson M, Byrne B, Bergin DA, Smith SG, Greally P, O'Kennedy R, O'Neill SJ, McElvaney NG. IL-8 dictates glycosaminoglycan binding and stability of IL-18 in cystic fibrosis. J Immunol 2010;184:1642-1652.
45. Johnson Z, Proudfoot AE, Handel TM. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev 2005;16:625-636. (Pubitemid 41509199)
46. Spillmann DL, Lindahl U. Glycosaminoglycan-protein interactions, a question of specificity. Curr Opin Struct Biol 1994;4:677-682.
47. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997;94:14683-14688. (Pubitemid 28041434)
48. Lyon M, Gallagher JT. Bio-specific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion. Matrix Biol 1998;17:485-493. (Pubitemid 28566883)
49. Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007;52:1176-1193; discussion 1193-1197.
50. Aitken ML, Greene KE, Tonelli MR, Burns JL, Emerson JC, Goss CH, Gibson RL. Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis. Chest 2003;123:792-799. (Pubitemid 36315495)
51. Tabary O, Escotte S, Couetil JP, Hubert D, Dusser D, Puchelle E, Jacquot J. High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I kappa B kinase alpha pathway in response to extracellular NaCl content. J Immunol 2000;164:3377-3384. (Pubitemid 30149004)
52. Hashimoto S, Matsumoto K, Gon Y, Nakayama T, Takeshita I, Horie T. Hyperosmolarity-induced interleukin-8 expression in human bronchial epithelial cells through p38 mitogen-activated protein kinase. Am J Respir Crit Care Med 1999;159:634-640. (Pubitemid 29084892)
53. Mackerness KJ, Jenkins GR, Bush A, Jose PJ. Characterisation of the range of neutrophil stimulating mediators in cystic fibrosis sputum. Thorax 2008;63:614-620. (Pubitemid 351969254)
54. Gaggar A, Jackson PL, Noerager BD, O'Reilly PJ, McQuaid DB, Rowe SM, Clancy JP, Blalock JE. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008;180:5662-5669.
55. Perks B, Shute JK. DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: In vitro effects of mucolytics. Am J Respir Crit Care Med 2000;162:1767-1772.
56. Leavell KJ, Peterson MW, Gross TJ. Human neutrophil elastase abolishes interleukin-8 chemotactic activity. J Leuk Biol 1997;61:361-366. (Pubitemid 27149916)
57. Ordonez CL, Kartashov AI, Wohl ME. Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis. J Pediatr 2004;145:689-692. (Pubitemid 39440951)
58. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-534.
59. Pin I, Gibson PG, Kolendowicz R, Girgis-Gabardo A, Denburg JA, Hargreave FE, Dolovich J. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992;47:25-29.
60. Sagel SD, Sontag MK, Wagener JS, Kapsner RK, Osberg I, Accurso FJ. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr 2002;141:811-817. (Pubitemid 35471643)